White Paper

The End Of End Point Assays, How SPR Is Changing Analytics In Vaccine Design And Development

Source: Cytiva

By Michael Murphy, Ph.D., Biacore Application Scientist, Fredrik Sundberg, Ph.D., Global Director Strategic Technologies, and Paul Belcher, Ph.D., Product Strategy Manager, Cytiva

Cytiva 'CY13186-Y0A2758-m02Jun20

Overcoming analytical challenges during vaccine development and production with surface plasmon resonance (SPR)


The COVID-19 pandemic of 2020 was a wake-up call to the biopharmaceutical industry. Although the importance of having technologies in place to rapidly develop safe and effective vaccines against infectious diseases has been a running topic in the industry for years, it has never been more glaringly obvious than in the aftermath of the COVID-19 outbreak.

To competently fight such outbreaks capable of creating havoc on a global scale, vaccine development must occur at lightening pace, supported by best-in-class technologies. Newer, more efficient and accurate analytical tools play a major role in boosting the discovery, characterization, and development of vaccines. Among them, surface plasmon resonance (SPR) has emerged as a game-changing technology. It has been fast adopted by industry groups due to the rich, real-time information it offers related to molecular interactions.

This article describes in detail how SPR can be used to accelerate vaccine discovery and development by helping overcome analytical challenges that have plagued the industry for decades.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online